Avalo Therapeutics Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, everyone. Thanks for joining us again. I'm Alex Thompson, biotech analyst here at Stifel. Very happy to have Garry Neil, CEO of Avalo Therapeutics, for a fireside chat. Maybe to kick things off, Garry, if you want to give a quick overview of Avalo, and then we'll get into it.
Thanks, Alex. Thanks for having us here. Avalo is a company based outside of Philadelphia, AVTX. We are building an immunology company around the NLRP3 IL-1 beta axis, and our lead compound, abdakibart, is a high-affinity human anti-IL-1 beta monoclonal antibody. Our initial target indication is hidradenitis suppurativa, and we have finished phase II with a very successful trial, a LOTUS trial, and we are about to enter phase III with the drug. We're very excited about that. We have a couple of other compounds in the pipeline, most notably AVTX-010, which is our own PK-extended version of abdakibart. It's also a high-affinity IL-1 beta, and we're also about to announce a new indication in another therapeutic area, which we'll talk about that before the end of the year.
Great. Maybe to set the stage, do you want to lay out where we are right now in the current treatment landscape for HS and sort of where the key elements of unmet need are?
Right. HS is a very interesting and a very difficult disease, both for the patients and to treat. My friend Kristian Reich at MoonLake describes it as Crohn's disease of the skin, which I think is a pretty accurate description. I remember, I'm a gastroenterologist and a physician, and I do remember seeing occasional patients with it back in the day when I was in practice, but we thought it was quite rare. It turns out it's not. There are about 3 million patients who suffer from this disease, and there's a very, very high need. It's taken a long time for There's been a long time interval between initial patient presentation and referral to a specialist where they could get definitive therapy. It's often misdiagnosed as boils or a rash rather than this severe autoinflammatory disease.
But as it's been increasingly recognized and biologic and targeted therapies have become available, there's been an explosion of recognition, growth, and development activity to try to bring new drugs to the market. The first of those was Humira, then Cosentyx, and now we have BIMZELX. So there are three drugs approved and several others in development. The market is projected, again, there are at least 3 million patients in the U.S. with it. It's projected to be over $10 billion. I think personally that may underestimate what the real market opportunity is, because I think the closest analog for me would be inflammatory bowel disease, which again, we thought was going to be a relatively small market, but has turned into a very large one with a lot of need.
It is not going to be a market which will be dominated by any single drug or single class of drugs, but we've seen success with anti-TNFs, with anti-IL-17s, and now with the anti-IL-1β class, a little bit with the JAKs as well, which are more of a rescue medication. But I think all of those are going to continue to grow. But we feel most bullish about the potential role of IL-1β in treating the disease, as IL-1β is a central driver of the inflammation. It's the most abundant cytokine found within these lesions, and it's a driver both of macrophage and neutrophil biology, the tissue destruction enzymes, but it's also upstream of TNF and IL-17, particularly IL-17F. So it's playing a more central role and has a very, very good and well-tolerated side effect profile.
So we think it's going to find a real place, and we've been very, very pleased with the results from our own phase II program in that regard.
Yeah. I think that's a good jumping off point here, and we'll talk about trial conduct and the challenges of HS, but as you alluded to, you had a positive phase II study, it seems like ages ago, back in the spring. But could you walk through the design, some of the key takeaways from the LOTUS study?
Yeah. LOTUS was the largest phase II trial in HS done to date. We ran it to a pivotal standard and analyzed it as if it was a pivotal trial. 16-week study, three arms, two active drug, one placebo, 1:1:1 randomization. We studied two different dosing regimens, a 600 loading, 300 once a month dose, and a 300 loading with 150 every two-week dose. We were looking at two different dosing intervals over 16 weeks. What we found was very, very compelling efficacy. About 43% patients achieved, in both arms on drug, achieved a HiSCR75, 75% healing of their lesions. If you look, the response curves were nice and smooth. Some of the other programs that we've seen that were a little bit smaller, maybe weren't as rigorously run, showed some sawtoothing. These were nice and smooth.
curves, all of the secondary endpoints were positive. We're particularly gratified about the, what's called the IHS4 scale, which is a non-binary type. It's a linear measurement, so a little bit less confounded by placebo, but it's heavily weighted towards abscesses, deeper lesions, and draining tunnels, where we did very well. So our IHS4 75 data at 44.7%, I think the highest that's been recorded to date in an HS trial.
The consistency of the data over time, across endpoints, and across both doses was remarkable, and therefore, we have very high confidence going into phase III that we're going to be able to replicate that.
Yep. I think the other big element of this trial too was safety, right?
Yeah questions around infection risk in this population and with this mechanism, and also things like neutropenia.
Can you talk a little about safety?
Yeah, that's really a great point because neutropenia has been associated with IL-1β blockade. The reason for that is that IL-1β drives G-CSF, which brings neutrophils out of the bone marrow and stimulates neutrophil growth. You tend to see real clinically significant neutropenia very rarely, though. If you look at the CANTOS trial, which was a three-year trial run by Novartis with their anti-IL-1, they showed a fatal neutropenic infection in 0.3 patients per 100 years of exposure on drug, 0.2 on placebo. So, a very small difference. You'd need a large trial to show it, but still, that was there. Now, in our study, these patients with HS have very high neutrophil counts to begin with. They're very inflamed, high CRP levels. We weren't really expecting a lot of neutropenia. Their neutrophil counts are high, and we didn't see it.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
